Cempra (CEMP) Tops Q3 EPS by 2c

Go back to Cempra (CEMP) Tops Q3 EPS by 2c

Cempra Reports Third Quarter 2016 Financial Results and Provides Corporate Update

October 27, 2016 4:15 PM EDT

CHAPEL HILL, N.C., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter ended September 30, 2016 and provided an update on recent corporate developments. The company will host a webcast and conference call today at 5:00 p.m. EDT.

Third Quarter 2016 and Recent Corporate Highlights

On October 25, Cempra completed enrollment in its ongoing Phase 3 study of... More

Cempra to Report Third Quarter 2016 Financial Results

October 25, 2016 4:15 PM EDT

CHAPEL HILL, N.C., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report third quarter 2016 financial results after the close of U.S. financial markets on Thursday, October 27, 2016. Cempra management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-377-7553 for domestic callers... More